These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16913439)

  • 1. Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.
    Park CG; Ahn JC; Hong SJ; Kim EJ; Lee SJ; Park SM; Seo HS; Oh DJ
    Korean J Intern Med; 2006 Jun; 21(2):103-8. PubMed ID: 16913439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
    Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
    J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
    Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irbesartan improves arterial compliance more than lisinopril.
    Ali K; Rajkumar C; Fantin F; Schiff R; Bulpitt CJ
    Vasc Health Risk Manag; 2009; 5(4):587-92. PubMed ID: 19649309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D; Malmqvist K; Held C; Kahan T
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
    Nyström F; Malmqvist K; Ohman KP; Kahan T
    J Hypertens; 2002 Aug; 20(8):1527-33. PubMed ID: 12172314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
    Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis.
    Georgianos PI; Agarwal R
    Am J Kidney Dis; 2015 Aug; 66(2):305-12. PubMed ID: 25818679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.
    Gaudio C; Ferri FM; Giovannini M; Pannarale G; Puddu PE; Vittore A; Fera MS; Vizza CD; Fedele F
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):622-8. PubMed ID: 14576510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Hallberg P; Lind L; Billberger K; Michaelsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
    Clin Cardiol; 2004 Mar; 27(3):169-73. PubMed ID: 15049387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K; Ohman KP; Lind L; Nyström F; Kahan T
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.